Inhaled insulin
- 4 May 2006
- Vol. 332 (7549) , 1043-1044
- https://doi.org/10.1136/bmj.332.7549.1043
Abstract
Footnotes Competing interests EJB has received consulting fees, speaking fees and a research grant from Pfizer pharmaceuticals, the manufacturer of Exubera, the first inhalable insulin preparation.Keywords
This publication has 12 references indexed in Scilit:
- Dissociation of Lung Function Changes with Humoral Immunity during Inhaled Human Insulin TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetesDiabetologia, 2006
- Antibody Response to Inhaled Insulin in Patients with Type 1 or Type 2 Diabetes. An Analysis of Initial Phase II and III Inhaled Insulin (Exubera) Trials and a Two-Year Extension TrialJournal of Clinical Endocrinology & Metabolism, 2005
- Inhalation of Insulin (Exubera) Is Associated With Augmented Disposal of Portally Infused Glucose in DogsDiabetes, 2005
- Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 1 DiabetesDiabetes Care, 2004
- Patient Satisfaction and Glycemic Control After 1 Year With Inhaled Insulin (Exubera) in Patients With Type 1 or Type 2 DiabetesDiabetes Care, 2004
- Inhaled Insulin Provides Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral AgentsA Randomized Controlled TrialArchives of internal medicine (1960), 2003
- Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimenClinical Therapeutics, 2002
- Treatment Satisfaction With Inhaled Insulin in Patients With Type 1 DiabetesDiabetes Care, 2001
- Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes MellitusAnnals of Internal Medicine, 2001